API Inhibitor Tofacitinib Material Tofacitinib Powder Tofacitinib

China API Inhibitor Tofacitinib Material Tofacitinib Powder Tofacitinib, Find details about China Tofacitinib, Inhibitor Tofacitinib from API Inhibitor Tofacitinib Material Tofacitinib Powder Tofacitinib

Basic Info.

Model NO.

Condavo-Tofacitinib

Name

Tofacitinib

Product Name

Tofacitinib Powder

Appearance

White Powder

Color

White Color

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Assay

99%

Grade

Medicine Grade

COA

Available

CAS

540737-29-9

C22h28n6o8

504.497

Psa

221.04000

Logp

0.23418

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Model NO.

Condavo-Tofacitinib

Name

Tofacitinib

Product Name

Tofacitinib Powder

Appearance

White Powder

Color

White Color

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Assay

99%

Grade

Medicine Grade

COA

Available

CAS

540737-29-9

C22h28n6o8

504.497

Psa

221.04000

Logp

0.23418

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Product Desciption

API Inhibitor Tofacitinib Material Tofacitinib powder Tofacitinib

API Inhibitor Tofacitinib Material Tofacitinib Powder Tofacitinib

Product Name	Tofacitinib
CAS	540737-29-9
Appearance	White crystalline powder
MF	C22H28N6O8
MW	504.497
Purity	99%
Shelf Life	2 Years

The chemical system name of tofacitib citrate is 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl) -Piperidin-1-yl]-3-oxo-propionitrile citrate, a Janus kinase inhibitor developed by Pfizer in the United States. On November 6, 2012, the U.S. Food and Drug Administration (FDA) approved the substance as a drug for the treatment of moderate to severely active rheumatoid arthritis (RA) with insufficient response or intolerance to methotrexate therapy. Treatment of adult patients.

API Inhibitor Tofacitinib Material Tofacitinib Powder Tofacitinib

API Inhibitor Tofacitinib Material Tofacitinib Powder Tofacitinib Tofacitinib is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and other countries. It has demonstrated effectiveness in the treatment of psoriasis in Phase 3 studies. It is being studied for the treatment of inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection.
API Inhibitor Tofacitinib Material Tofacitinib Powder Tofacitinib

Tofacitinib is suitable for moderate to severely active rheumatoid arthritis (RA) adult patients with insufficient or intolerable methotrexate efficacy. It can be combined with methotrexate or other non-biological anti-rheumatic drugs to improve the condition (DMARD) Used in combination.

API Inhibitor Tofacitinib Material Tofacitinib Powder Tofacitinib